Latest
Upstox Market update
News archive search
Search the Newsreel
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
- Showing
- 1–31
- Matches
- 31
- Sources here
- 20
- Companies here
- 3
Search results
Stored financial headlines
Active search
31 matching headlines
Ticker or company: COCHMain company stories
Search results
Matching headlines
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Lucid Capital Markets initiates Envoy Medical stock with buy rating By Investing.com
Lucid Capital Markets has initiated coverage on Envoy Medical (NASDAQ:COCH) with a buy rating and a price target of $2.00, representing a 203% upside. The firm highlighted Envoy’s fully implanted cochlear implant device, Acclaim, which offers 24/7 hearing without external components and has received …
COCH
main company
Sharemaestro market context
Trend signal started
52 weeks -30.4%
EXCLUSIVE: Envoy Medical Hits Key Clinical Trial Milestone for Fully Implanted Ear Implant
Envoy Medical has reached a significant milestone, surpassing the three-month mark for all 56 patients in its pivotal clinical trial for the Acclaim cochlear implant. The company is on track for FDA submission and anticipates achieving six-month and twelve-month visit milestones by late 2026 …
COCH
main company
Sharemaestro market context
Trend signal started
52 weeks -30.4%
All 56 patients reach 3 months in Envoy Medical's hearing implant trial
Envoy Medical (NASDAQ: COCH) announced that all 56 patients in its pivotal clinical trial for the investigational Acclaim cochlear implant have completed their three-month visit milestone. This achievement is a crucial step toward the company's planned Premarket Approval (PMA) submission to the U.S. FDA. …
COCH
main company
Sharemaestro market context
Trend signal started
52 weeks -30.4%
Envoy Medical Surpasses Three-Month Visit Milestone for All 56 Patients in Pivotal Clinical Trial
Envoy Medical Inc. announced that all 56 patients in its pivotal clinical trial for the investigational fully implanted Acclaim® cochlear implant have surpassed the three-month visit milestone. This achievement brings the company closer to submitting its Premarket Approval application to the FDA for the …
COCH
main company
Sharemaestro market context
Trend signal started
52 weeks -30.4%
EXCLUSIVE: Envoy Medical Builds Momentum With Improved Cochlear Implant Trial Results
Envoy Medical Inc. reported improved 12-month results from Stage 1 of its pivotal clinical trial for the Acclaim cochlear implant, showing a significant increase in hearing performance compared to baseline and six-month data. Participants achieved a mean CNC word recognition score of 53.2% at …
COCH
main company
Sharemaestro market context
Trend signal started
52 weeks -30.4%
H.C. Wainwright reiterates Envoy Medical stock rating on trial progress By Investing.com
H.C. Wainwright has reiterated a Buy rating and a $2.50 price target for Envoy Medical (NASDAQ:COCH) after an update on the pivotal trial of its Acclaim cochlear implant. The company announced that the first three patients have completed their 12-month endpoint visits, with topline …
COCH
main company
Sharemaestro market context
Trend signal started
52 weeks -30.4%
Envoy Medical Reports Positive 12-Month Data Showing Continued Improvement in Speech Perception in Study of First-of-Its-Kind Fully Implanted Cochlear Implant
Envoy Medical announced positive 12-month data from Stage 1 of its pivotal clinical trial for the Acclaim® fully implanted cochlear implant, showing significant improvements in speech perception. The study's first 10 participants demonstrated a substantial increase in CNC word recognition scores, with continued improvement …
COCH
main company
Sharemaestro market context
Trend signal started
52 weeks -30.4%